English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Results At the end of follow-up, we observed a global stability for diagnosis in 93% of patients and for the choice of primary anti-manic drug therapy in 74%. In case of changing primary treatment, almost half of changes were done within the same drug family and half toward a switch to another family. At D180, the switch rate from MS to AP was 5% and from AP to MS 14.5%. The global rate of treatment modifications (including changing of dose) was 44% at D15, 42% at D30, 34% at D60, 35% at D90, 32% at D180, and the major reason for modifications was partial efficacy (respectively 17.5%, 15%, 9.4%, 12.2% and 9.4%). Intolerance was the second reason (respectively 8%, 6.3%, 7%, 4.2% and 3.8%).

Drug treatment of mania: 6 month prospective follow-up in a naturalistic multi-site survey